Results 161 to 170 of about 3,079 (276)

An XGBoost‐Based Multicenter Model for Predicting HBV‐Related Hepatocellular Carcinoma: Development and Validation

Cancer Medicine, Volume 15, Issue 5, May 2026.
We developed a web‐based interactive tool to estimate individualized HCC risk in chronic HBV patients, enabling clinicians to input real‐time data for personalized risk probabilities and evidence‐based actionable recommendations. ABSTRACT Background The 5‐year survival rate for hepatocellular carcinoma (HCC) is stage‐dependent, yet existing models lack
Yong Lin, Hai‐Yan Zhuo, Hui‐Wen Song, Li‐Na Zhou, Mei‐Zhu Hong, Chun Lin, Peng‐Fei Guo, Jin‐Shui Pan   +7 more
wiley   +1 more source

Evaluating the GALAD Score for Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. [PDF]

J Clin Gastroenterol
Vo TD, Mai SH, Lam HT.
europepmc   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

Beyond conventional biomarkers: the role of alpha-fetoprotein in gastroenteropancreatic neuroendocrine neoplasms. [PDF]

Front Endocrinol (Lausanne)
La Salvia A, Fanciulli G.
europepmc   +1 more source

The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Aims To explore a safe and effective treatment modality for unresectable huge (≥ 10 cm) hepatocellular carcinoma with portal vein thrombosis. And to provide more data on the synergistic antitumor effects of radiotherapy combined with immune checkpoint inhibitors and antiangiogenic therapy. Materials and Methods This study compared the clinical
ZengLiang Huang, ZhongHua Chen, JuanJuan Shen, JianHai Lin, ShiLong Den, NanBao Zhong   +5 more
wiley   +1 more source

Phosphopeptidome Profiling of Human Plasma for Hepatocellular Carcinoma Biomarker Discovery. [PDF]

J Proteome Res
Saleem S, Sajid MS, Varghese RS, Sherif ZA, Kroemer A, Ressom HW.   +5 more
europepmc   +1 more source

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
NCCT radiomics for surufatinib efficacy prediction in HM‐NENs. ABSTRACT Background Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs.
Miaomiao Feng, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin   +5 more
wiley   +1 more source

Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients. [PDF]

Virulence
Li J, Li H, Lin C, Jiang R, Wang L, He Y, Yang X, Gong K, Xun Z, Zheng Q.   +9 more
europepmc   +1 more source

A Real‐World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First‐Line Lenvatinib

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Introduction Lenvatinib is approved as a first‐line treatment for unresectable hepatocellular carcinoma (HCC), but real‐world outcomes may vary due to patient heterogeneity. This study aimed to evaluate the real‐world efficacy of lenvatinib in Taiwanese patients and to identify prognostic factors influencing outcomes.
Shou‐Wu Lee, Yi‐Jie Huang, Hsin‐Ju Tsai, Ying‐Cheng Lin, Chia‐Chang Chen, Teng‐Yu Lee, Yen Chun‐Peng   +6 more
wiley   +1 more source

Integration of circulating biomarkers and clinical factors: construction and validation of a prediction model for lung cancer metastasis. [PDF]

BMC Pulm Med
Qi W, Li Z, Xu J, Wang T.
europepmc   +1 more source